Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Pharmacists Are Absent from 64% of Stores Selling Drugs at Night
August 27, 2001
- Price Adjustment Method No Longer Functions Properly: Mr Fujii, New Diet Member
August 27, 2001
- OCT NEWS IN BRIEF
August 27, 2001
- Economic Reform Should Not Affect Quality of Social Security Services: Mr Takemi, Lower House Member
August 27, 2001
- Yamanouchi Discovers Immunocompetent Cell Activating Gene
August 27, 2001
- Innovex to Establish Japan's 1st MR Syndicate Team Next Year: Mr Feldman
August 27, 2001
- Stage 2 Schedule Set for Quality Reevaluation of 249 Ingredients
August 27, 2001
- Genomic Analysis by Industry, Government, Academia Started
August 27, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -2-
August 27, 2001
- Launching of Tarivid Generics Postponed Due to Patent Problems
August 27, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
August 27, 2001
- Nosan Corporation Ties Up with Midwest Research Institute
August 27, 2001
- Quality Reevaluation Enters Step 4 for 28 Ingredients
August 27, 2001
- MEDICAL DEVICE NEWS IN BRIEF
August 27, 2001
- Kirin Forms Research Alliance with Hyseq
August 27, 2001
- Use of Orange Book, Rx in Generic Name Recommended for Promotion of Generics: EAD Director
August 27, 2001
- Fujirebio, diaDexus Tie Up to Develop Cancer Diagnostic Agents
August 27, 2001
- Alendronate to Change Market for Osteoporosis
August 27, 2001
- REGULATORY NEWS IN BRIEF -1-
August 27, 2001
- Genzyme to Switch to Quatro Test for Maternal Serum Testing
August 27, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…